卡泊芬净治疗异基因造血干细胞移植术后侵袭性真菌感染
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
卡泊芬净治疗异基因造血干细胞移植术后侵袭性真菌感染
白海涛;王椿;万理萍;姜杰玲;杨隽;蔡宇
【期刊名称】《上海交通大学学报(医学版)》
【年(卷),期】2013(033)004
【摘要】Objective To investigate the efficacy and safety of Caspofungin
for the treatment of invasive fungal infections after allogeneic hematopoietic stem cell transplantation ( allo-HSCT). Methods Thirty-nine cases of invasive fungal infections after allo-HSCT were selected, stratified diagnosis was made according to the standard of European Organization
for Research on Treatment of Cancer ( EORTC), and treatment with intravenous Caspofungin was performed. The initial dosage and maintenance dosage were 70 mg/d and 50 mg/d respectively, with time of infusion more than 1 h and course of treatment ranging from 14 d to 42 d. Imaging and microbiological examinations were carried out weekly before treatment and in the course of treatment. Side effects were assessed after treatment. Results The overall favorable response to Caspofungin was 76.9% (30/39). The response rates of confirmed cases, clinically diagnosed cases and suspected cases were 100% (3/3), 73.7% (14/19) and 76.5% (13/17) respectively. There was no significant difference in the response rates between clinically diagnosed cases and suspected cases (P > 0. 05). Three cases had mild liver function abnormalities, and hypokalemia occurred in 4 cases. Conclusion Caspofungin is an effective agent with minimal adverse
effects for treatment of invasive fungal infections after allo-HSCT.%目的观察卡泊芬净治疗异基因造血干细胞移植(allo-HSCT)术后患者深部真菌感染的疗效和安全性.方法收集39例诊断为深部真菌感染的allo-HSCT术后患者,按照欧洲癌症治疗研究组织(EORTC)的诊断标准分层诊断,给予静脉卡泊芬净治疗.卡泊芬净首日负荷剂量70 mg/d,维持剂量50 mg/d,输注时间≥1h,疗程14~42 d.患者治疗前和治疗期间每周进行影像学检查和微生物学检验;治疗后进行药物不良反应评价.结果 39例allo-HSCT术后侵袭性真菌感染患者经卡泊芬净治疗后,总有效率为76.9% (30/39);3例确诊病例的有效率为100%(3/3),临床诊断病例有效率为73.7% (14/19),拟诊病例为76.5%(13/17).临床诊断病例和拟诊病例的有效率比较差异无统计学意义(P>0.05).3例患者出现轻度肝功能异常,4例出现低血钾.结论卡泊芬净治疗真菌感染的疗效高,不良反应少,有望作为治疗allo-HSCT患者侵袭性真菌感染的一线用药.
【总页数】4页(P468-470,475)
【作者】白海涛;王椿;万理萍;姜杰玲;杨隽;蔡宇
【作者单位】上海交通大学附属第一人民医院血液科,上海200080
【正文语种】中文
【中图分类】R551;R379
【相关文献】
1.卡泊芬净治疗肺部侵袭性真菌感染老年患者的疗效观察 [J], 冯静;毋娜;朱卫华;杜志强
2.卡泊芬净治疗重症患者侵袭性真菌感染的疗效与安全性 [J], 段杏华
3.卡泊芬净与伏立康唑治疗侵袭性真菌感染的疗效评价 [J], 程丽华; 王艳; 林树东;
李亚东; 田海容
4.卡泊芬净与伏立康唑治疗侵袭性真菌感染的疗效评价 [J], 程丽华; 王艳; 林树东; 李亚东; 田海容
5.卡泊芬净治疗新生儿侵袭性真菌感染的临床疗效和安全性 [J], 孙冲;张潇月;李燕;马姝丽
因版权原因,仅展示原文概要,查看原文内容请购买。